Surrozen, Inc. develops drugs that target the Wnt pathway to promote tissue repair and regeneration in various disease areas. Its pipeline includes SZN-043 for the treatment of severe liver disease, and SZN-1326, a bi-specific antibody that modulates Wnt signaling in intestinal tissue. Founded in 2015, Surrozen is a biotech company headquartered in South San Francisco, California.